No profile data available.
TScan Therapeutics, Inc. (TCRX) is a healthcare company in the additional cancer treatment drugs industry, based in Waltham, United States, with about 138 full-time employees.
It reported revenue of $10.33 million for fiscal year 2025, up 266.7% from fiscal year 2024, and net income of -$129.77 million. Its market capitalization was $15.55 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
TScan Therapeutics reported $10.33 million in revenue for fiscal year 2025, up 266.7% from $2.82 million in fiscal year 2024.
$15.55 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Abpro Holdings, Inc. (ABP), Allarity Therapeutics, Inc. (ALLR), Pasithea Therapeutics Corp. (KTTA), Actuate Therapeutics, Inc. Common stock (ACTU).